Devirex patent approved in China

2017-04-19 12:00

A patent for lipivir® for the prevention of cold sores has been granted to Devirex AG by the Chinese Patent Office. Following completion of a successful clinical study at the University of Zurich in which it was demonstrated a previously completely unknown effect of the components of lipivir®, the management team of Devirex filed for patents in all relevant geographies of the world.

The approval of this patent means that lipivir® (polyethylene glycols) for the prevention of Herpes Simplex diseases (cold sores, genital herpes, herpes Zoster) is protected as Intellectual Property of Devirex AG in China. China and the World Intellectual Property Organization (WIPO) signed a memorandum of understanding to enhance partnership in the field of intellectual property (IP) protection on May 11, 2016 in Geneva.

Devirex’ portfolio of patents comprise a broad range of formulations of different polyethylene glycols for the prevention of all herpes diseases.

“This is excellent news for us as we now have protection of our Intellectual Property in China, the world’s most populous country market and can start seeking the right distribution partners for this highly important market!” commented Devirex CEO Paul Scherer.

Back to news